Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0648

+8.0%

Nov 11 3:24 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

boomertree2

Jack Russell

Littlebits

From: Howard Williams	10/18/2013 9:18:21 AM
	3 Recommendations of 13111

Provectus News [Video] Phase 2 Study of Intralesional PV-10 (Rose Bengal) in Metastatic Melanoma Friday October 18, 2013 In a video appearing on Pharmacy & Therapeutics' P&T TV, Sanjiv Agarwala, MD, of Temple University in Philadelphia, PA, discusses several scenarios in which PV-10 might be used if it is ultimately approved for patients with advanced melanoma. The video may be viewed on the Provectus website, courtesy of www.ptcommunity.com (MediMedia USA, Inc., publishers), at the below link. pvct.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next